Asset Management One Co. Ltd. Reduces Position in Kenvue Inc. $KVUE

Asset Management One Co. Ltd. decreased its position in Kenvue Inc. (NYSE:KVUE) by 0.5% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 797,424 shares of the company’s stock after selling 3,952 shares during the quarter. Asset Management One Co. Ltd.’s holdings in Kenvue were worth $16,690,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in Kenvue by 4.9% in the first quarter. Vanguard Group Inc. now owns 229,144,387 shares of the company’s stock worth $5,494,882,000 after purchasing an additional 10,600,682 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Kenvue by 2.5% in the first quarter. Charles Schwab Investment Management Inc. now owns 25,606,238 shares of the company’s stock worth $613,882,000 after purchasing an additional 633,461 shares in the last quarter. Boston Partners raised its holdings in Kenvue by 7.4% in the first quarter. Boston Partners now owns 25,346,453 shares of the company’s stock worth $606,920,000 after purchasing an additional 1,750,490 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Kenvue by 11.6% in the first quarter. JPMorgan Chase & Co. now owns 24,912,226 shares of the company’s stock worth $597,395,000 after purchasing an additional 2,597,920 shares in the last quarter. Finally, American Century Companies Inc. raised its holdings in Kenvue by 15.7% in the first quarter. American Century Companies Inc. now owns 21,828,854 shares of the company’s stock worth $523,456,000 after purchasing an additional 2,961,716 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Analysts Set New Price Targets

KVUE has been the subject of a number of research reports. Canaccord Genuity Group decreased their price objective on Kenvue from $29.00 to $26.00 and set a “buy” rating for the company in a report on Friday, August 8th. Zacks Research upgraded Kenvue to a “strong sell” rating in a report on Monday, August 11th. Barclays reduced their price target on Kenvue from $20.00 to $17.00 and set an “equal weight” rating for the company in a report on Wednesday, October 1st. Citigroup reduced their price target on Kenvue from $20.00 to $17.00 and set a “neutral” rating for the company in a report on Thursday, October 9th. Finally, Royal Bank Of Canada reduced their price target on Kenvue from $24.00 to $22.00 and set a “sector perform” rating for the company in a report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Kenvue currently has an average rating of “Hold” and a consensus price target of $20.75.

Kenvue Price Performance

NYSE KVUE opened at $15.00 on Friday. Kenvue Inc. has a one year low of $14.05 and a one year high of $25.17. The stock has a 50-day moving average of $17.91 and a 200 day moving average of $20.79. The company has a market capitalization of $28.78 billion, a price-to-earnings ratio of 20.26, a PEG ratio of 2.16 and a beta of 0.72. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.98.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.29 EPS for the quarter, topping the consensus estimate of $0.28 by $0.01. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The company had revenue of $3.84 billion during the quarter, compared to the consensus estimate of $3.94 billion. During the same period last year, the company earned $0.32 EPS. Kenvue’s revenue for the quarter was down 4.0% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, sell-side analysts forecast that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, August 27th. Investors of record on Wednesday, August 13th were issued a $0.2075 dividend. This represents a $0.83 annualized dividend and a yield of 5.5%. The ex-dividend date was Wednesday, August 13th. This is a positive change from Kenvue’s previous quarterly dividend of $0.21. Kenvue’s dividend payout ratio is 112.16%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.